Iambic Therapeutics
PublicIambic Therapeutics is now publicly traded
The data on this page reflects Iambic Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Aug 14, 2026
Total Funding Raised
$446.73M
Company Overview
Iambic Therapeutics operates in Biotech and is based in San Diego, California. It has raised $446.73M.
Iambic Therapeutics is a biotechnology company that develops an AI-driven drug discovery platform to create novel medicines for cancer and other diseases.
Sector
Biotech
Verticals
Artificial Intelligence & Machine Learning, Digital Health, HealthTech, Life Sciences, Oncology
AI Layer
Application
Iambic Therapeutics Comparables
Compare Iambic Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genesis Therapeutics | 88% | |
| Valo Health | 87% | |
| Terray Therapeutics | 87% |
For institutional investors. Book with your work email.
Iambic Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 14, 2026 | ||||
| Early Stage VC | Apr 1, 2026 | ||||
| VC Round | Nov 10, 2025 | ||||
| Series B Extension | Jun 18, 2024 | ||||
| Series B | Oct 3, 2023 | ||||
Series A | Jul 14, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Iambic Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B |
| OrbiMed | Series B, Series A |
| Catalio Capital Management | Series B, VC Round, Series A |
| Freeflow Ventures | VC Round |
| Sequoia Capital | Series B, Series A, VC Round |
| Abingworth | Series B Extension, VC Round, Series B |
| Shanda Capital | Series B |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_valuation_increased_byOct 15, 2026
Iambic Therapeutics, Inc.'s valuation increases 16% after a $150 million IPO on Oct 15th '26.
- has_lossOct 9, 2026
For the six months ended Jun 30th '26, Iambic Therapeutics, Inc. reports a net loss of $50.1M on $12.8M in revenue.
- has_revenueOct 9, 2026
Iambic Therapeutics, Inc. reports $12.8M in revenue for the six months ended Jun 30th '26, alongside a US$50.1 million net loss.
- is_developingOct 9, 2026
Iambic Therapeutics, Inc. plans to continue developing its AI platform with $20m in IPO proceeds, and the platform has attracted partnership deals with AbbVie, Takeda, Lundbeck, Revolution Medicines, Jazz Pharma, and Bayer.
- has_revenueOct 9, 2026
Iambic Therapeutics, Inc. reports $9.4M in collaboration revenue from pharma partnerships in 2025 and is based in California.
For institutional investors. Book with your work email.
Iambic Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.